Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) Operating Margin (2019 - 2025)

Burning Rock Biotech has reported Operating Margin over the past 7 years, most recently at 9.53% for Q4 2025.

  • For Q4 2025, Operating Margin rose 5548.0% year-over-year to 9.53%; the TTM value through Dec 2025 reached 10.16%, up 5886.0%, while the annual FY2025 figure was 10.17%, 5915.0% up from the prior year.
  • Operating Margin for Q4 2025 was 9.53% at Burning Rock Biotech, up from 12.26% in the prior quarter.
  • Over five years, Operating Margin peaked at 7.74% in Q2 2025 and troughed at 202.9% in Q2 2022.
  • A 5-year average of 107.42% and a median of 133.67% in 2021 define the central range for Operating Margin.
  • Biggest five-year swings in Operating Margin: plummeted -9046bps in 2021 and later soared 11016bps in 2024.
  • Year by year, Operating Margin stood at 171.11% in 2021, then grew by 11bps to 152.88% in 2022, then increased by 10bps to 137.37% in 2023, then skyrocketed by 53bps to 65.01% in 2024, then skyrocketed by 85bps to 9.53% in 2025.
  • Business Quant data shows Operating Margin for BNR at 9.53% in Q4 2025, 12.26% in Q3 2025, and 7.74% in Q2 2025.